Multiple Sclerosis (MS) Drug Market

RECENT NEWS
Clusterstock  Apr 25  Comment 
Delta Air Lines passenger Maria Saliagas was reportedly tied to a wheelchair with a blanket after the airline failed to provide the correct wheelchair, according to WSB-TV. Her son, Nathan, said Delta did not fulfill his request for a wheelchair...
MedPage Today  Apr 23  Comment 
(MedPage Today) -- AAN updates multiple sclerosis treatment recommendations
FiercePharma  Apr 20  Comment 
Novartis is hoping its multiple sclerosis candidate siponimod’s performance in secondary progressive patients can help secure it a blockbuster approval. And now it has more data to put toward that case.
GenEng News  Apr 17  Comment 
Scientists at the Karolinska Institute in Sweden say they have developed a new disease model for neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) that can be used to develop new immunotherapies....
FiercePharma  Apr 5  Comment 
Crowding in the multiple sclerosis field hasn’t stopped new Roche drug Ocrevus from making a splash. But that competition is making it tough for the Swiss drugmaker to snag reimbursement in England.
FierceBiotech  Mar 8  Comment 
A phase 2a trial of Merck KGaA’s BTK inhibitor evobrutinib has hit its primary endpoint. The prospect chalked up the win by reducing gadolinium-enhancing T1 lesions by more than placebo, but Merck has yet to quantify the difference or say how it...
FiercePharma  Mar 7  Comment 
Less than a week after announcing that they were “urgently reviewing” AbbVie and Biogen's multiple sclerosis drug Zinbryta on safety concerns, European regulators are recommending an immediate suspension and recall of the product.
MarketWatch  Mar 2  Comment 
Biogen Inc. and AbbVie Inc. said early Friday that the companies are voluntarily withdrawing their relapsing multiple sclerosis drug, Zinbryta, from global markets. Biogen shares declined 1.6% and AbbVie shares dropped 1.3% in premarket trade....
FierceBiotech  Feb 28  Comment 
The FDA has refused to review a filing for approval of Celgene’s key pipeline prospect ozanimod. The agency hit the big biotech with the embarrassing refusal-to-file notice after concluding it had failed to provide the necessary preclinical and...
MarketWatch  Feb 27  Comment 
Celgene Corp. shares dropped in the extended session Tuesday after the biotech drug maker said the Food and Drug Administration would not accept a drug marketing application for a multiple sclerosis treatment. Celgene shares dropped 7% after...




 
TOP CONTRIBUTORS

Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki